Home
BridgeBio Pharma product BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio Pharma product BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Impacting News March 12, 2026

BridgeBio Pharma in the NEWS
On March 11, 2026, BridgeBio Pharma (BBIO) presented additional positive data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in individuals with limb-girdle muscular dystrophy type . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
March 12, 2026

Other Articles